trending Market Intelligence /marketintelligence/en/news-insights/trending/2eedgi9bwnexgeajxf1nzq2 content esgSubNav
In This List

Halozyme appoints former Bristol-Myers exec as chief commercial officer

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Halozyme appoints former Bristol-Myers exec as chief commercial officer

Halozyme Therapeutics Inc. appointed Benjamin Hickey as chief commercial officer, effective Sept. 10.

The San Diego-based company said Hickey will build and execute the commercial strategy for its oncology portfolio, beginning with the investigational drug pegvorhyaluronidase alfa, or PEGPH20, if approved.

Hickey previously served as general manager for U.K. and Ireland at Bristol-Myers Squibb Co. During his 17-year career at Bristol-Myers, Hickey also served as vice president of marketing for immuno-oncology, where he led the commercialization of blockbuster cancer drug Yervoy and oversaw the launch preparedness of Opdivo, another blockbuster cancer drug.